Repositório Covid-19

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes coronavirus disease 2019 (COVID-19). SARS-CoV-2 enters host cells by binding with the...

Patients with underlying medical conditions are at increased risk for severe coronavirus disease 2019 (Covid-19). Whereas vaccine-derived immunity develops over...

An ideal therapeutic anti-SARS-CoV-2 antibody would resist viral escape1,2,3, have activity against diverse sarbecoviruses4,5,6,7, and be highly protective through viral...

Development of an effective antiviral drug for Coronavirus Disease 2019 (COVID-19) is a global health priority. Although several candidate drugs...

The emergency use authorization of two mRNA vaccines in less than a year from the emergence of SARS-CoV-2 represents a...

Improving clinical care for individuals infected with SARS-CoV-2 variants is a global health priority. Small-molecule antivirals like remdesivir (RDV) and...

The COVID-19 pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has quickly spread around the globe. At...

The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1,2,3,4,5. Since then, it has become dominant in some regions...

The genetic make-up of an individual contributes to the susceptibility and response to viral infection. Although environmental, clinical and social...

Mass vaccination campaigns to prevent coronavirus disease 2019 (Covid-19) are occurring in many countries; estimates of vaccine effectiveness are urgently...

Vaccine-induced immune thrombotic thrombocytopaenia (VITT) is a rare adverse effect of COVID-19 adenoviral vector vaccines1,2,3. VITT resembles heparin-induced thrombocytopaenia (HIT)...

The novel coronavirus SARS-CoV-2, responsible for the present COVID-19 global pandemic, is known to bind to the angiotensin converting enzyme-2...